Send to

Choose Destination
Curr Oncol Rep. 2001 May;3(3):223-7.

STI571: a gene product-targeted therapy for leukemia.

Author information

Leukemia Program, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health Sciences University, OP28, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA.


Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center